Contact us Demo our platform

Case Study

Diagnosing and Treating SLC13A5-Epilepsy Patients

Metabolomics could provide a less expensive and more expeditious method to investigate potential diagnoses for SLC13A5-epilepsy patients analogously to genome-wide sequencing.

Metabolon helped this group elucidate alterations in the plasma, cerebrospinal fluid (CSF), EDTA plasma, and urine of SLC13A5-epilepsy patients. Elucidating perturbations of metabolism is also crucial for the exploration of potential therapeutic approaches in the hopes of controlling seizures.

Talk With An Expert About Your Project

Metabolon helped this group elucidate alterations in the plasma, cerebrospinal fluid (CSF), EDTA plasma, and urine of SLC13A5-epilepsy patients. Elucidating perturbations of metabolism is also crucial for the exploration of potential therapeutic approaches in the hopes of controlling seizures.

Talk With An Expert About Your Project
SLC13A5

The Challenge: Diagnosing Rare Disease SLC13A5-Epilepsy

Epilepsy is a neurological disorder caused by various factors, including brain injury and genetic predisposition. Early Infantile Epileptic Encephalopathies (EIEE) are a heterogeneous group of rare genetic diseases characterized by severe seizures that begin in the first year of life, along with developmental delays and other neurological disorders. One of the subtypes of EIEE is caused by mutations in the SLC13A5 gene. Although genome-wide sequencing can provide a definitive diagnosis in these cases, clinical sequencing is expensive and has a relatively long turnaround time. Early diagnosis of a SLC13A5-related disorder is critical for developing better treatments and improving prognosis. Metabolomics could provide a less expensive and more expeditious method to investigate potential diagnoses analogously to genome-wide sequencing.

Metabolon Insight: Elucidating Perturbations in the Metabolome of SLC13A5-Epilepsy Patients

This study utilized the Metabolon Global Discovery Panel to profile the CSF, plasma, and urine of five confirmed SLC13A5-epilepsy patients and compared relative values of metabolites to unaffected control samples (N = 80, 78, 76 for urine, plasma, and CSF, respectively).1 The Metabolon Global Discovery Panel’s unrivaled coverage of over 5,400 semi-quantifiable metabolites offered this group the most comprehensive solution to characterize the metabolic changes due to SLC13A5 loss of function.

The Solution: Metabolomics Reveals Perturbed Metabolites in the Urine, Plasma, and CSF of SLC13A5-Epilepsy Patients

Metabolomics identified 893, 629, and 425 metabolites in the urine, plasma, and CSF, respectively. Analysis of urine, plasma, and CSF samples revealed 32 dysregulated metabolites in SLC13A5-epilepsy patients compared to controls. Most (25) of the perturbed metabolites were detected in the CSF. Metabolomics analysis also showed increased citrate levels in the CSF and the plasma of SLC13A5-epilepsy patients compared to controls. Citrate is produced by the tricarboxylic acid cycle (TCA), which is critical for brain function, not only for energy production but also as a supply of biosynthetic precursors for amino acids and neurotransmitters. Other TCA cycle-related metabolites were found to be perturbed in the urine (fumarate) and CSF (isocitrate, 2-methylcitrate & aconitate).

Analysis of patients’ CSF samples revealed consistent alterations in multiple metabolites associated with carbohydrate metabolism, lipid synthesis, and amino acid pathways. The most upregulated metabolite was 2-methylcitrate, having an approximate 4-fold increase in the relative amount in patient CSF compared to control. In contrast, 3-hydroxybutyrate (BHBA) was the most downregulated metabolite. In urine, fumarate was reduced in the subject samples compared to controls, demonstrating that disturbances of TCA cycle metabolites were detected in all three compartments.

The Outcome: Metabolomics May Provide Better Diagnosis and Treatment for SLC13A5-Epilepsy Patients

Metabolon helped this group elucidate alterations in the plasma, CSF, and urine of SLC13A5-epilepsy patients. The most significant finding was that citrate was highly elevated in the plasma and CSF of SLC13A5-epilepsy patients compared to controls. The perturbed metabolites revealed by this study could potentially be used as biomarkers to diagnose patients with SLC13A5-epilepsy. Diagnosing a SLC13A5-related disorder early is critical for focusing treatment, prognosis, and limiting unnecessary and redundant diagnostic tests. Identifying perturbations of metabolism is also crucial for the exploration of potential therapeutic approaches in the hopes of controlling seizures.

References

1. Bainbridge MN, Cooney E, Miller M, et al. Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle. Mol Genet Metab. Aug 2017;121(4):314-319. doi:10.1016/j.ymgme.2017.06.009

Related Case Studies

See All Case Studies
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.